In bladder cancer cells, pharmacologic inhibition of TBXAS1 with furegrelate or ozagrel induced apoptosis and enhanced sensitivity to chemotherapy,[92] which does suggest that pharmacologic inhibition of this enzyme has potential for treatment in AML. The gene discussed is TBXAS1; the disease is urinary bladder carcinoma.